Outlook: Cara Therapeutics gives investors a look at the books

At the financial conference taking place on May 9th, 2022, Cara Therapeutics will present the figures for the most recent quarter, which ended on March 31st, 2022.

7 analysts are on average estimating that Cara Therapeutics will report a loss per share of -$0.551 for the most recent quarter. In the prior year, the company had generated EPS of -$0.470 per share.

In terms of sales, 6 analysts estimate that the average for the past quarter was $2.6 million, an increase of 36.08 percent compared to the same quarter in the previous year. At the time, Cara Therapeutics had sales of $1.9 million.

With a view to the current fiscal year, 8 analysts are forecasting an average loss per share of -1.436 USD. In the previous year it was -$1,740 per share. In terms of sales, 8 analysts estimate on average that a total of USD 62.6 million should be sold in the current fiscal year, compared to USD 23.0 million in the same period last year.

Editorial office finanzen.net